Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Satellos Bioscience Inc (MSCLF)

Satellos Bioscience Inc (MSCLF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 171,223
  • Shares Outstanding, K 185,507
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,510 K
  • EBIT $ -27 M
  • EBITDA $ -24 M
  • 60-Month Beta 1.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.02
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.10
  • Most Recent Earnings $-0.03 on 11/14/25
  • Next Earnings Date 03/25/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4732 +95.05%
on 12/31/25
1.0000 -7.70%
on 01/28/26
+0.4256 (+85.56%)
since 12/29/25
3-Month
0.4419 +108.87%
on 11/14/25
1.0000 -7.70%
on 01/28/26
+0.3734 (+67.94%)
since 10/29/25
52-Week
0.3774 +144.57%
on 06/16/25
1.0000 -7.70%
on 01/28/26
+0.3323 (+56.26%)
since 01/29/25

Most Recent Stories

More News
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+

MSCLF : 0.9230 (+1.41%)
MSCL.TO : 16.05 (-0.62%)
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval

GBIO : 5.34 (-6.97%)
MSCLF : 0.9230 (+1.41%)
VRTX : 477.92 (+4.17%)
MSCL.TO : 16.05 (-0.62%)
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing

Satellos Bioscience Inc . (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines...

MSCLF : 0.9230 (+1.41%)
MSCL.TO : 16.05 (-0.62%)
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy

- Placebo-controlled Phase 2 study will evaluate SAT-3247 treatment over three months among ambulatory children with Duchenne - Study endpoints...

MSCLF : 0.9230 (+1.41%)
MSCL.TO : 16.05 (-0.62%)
Satellos to Participate in December Investor Conferences

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSCLF : 0.9230 (+1.41%)
MSCL.TO : 16.05 (-0.62%)
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy

Research confirms muscle stem cell dysfunction impairs polarity and impedes production of myogenic progenitors during fetal development Findings solidify...

MSCLF : 0.9230 (+1.41%)
MSCL.TO : 16.05 (-0.62%)
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors

Appointed Mark Nawacki, seasoned M&A expert, co-founder, president & former CEO of Searchlight Pharma, to Board of Directors Completed IND submission...

MSCLF : 0.9230 (+1.41%)
MSCL.TO : 16.05 (-0.62%)
Satellos to Participate in November Investor Conferences

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSCLF : 0.9230 (+1.41%)
MSCL.TO : 16.05 (-0.62%)
Satellos to Participate in November Investor Conferences

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSCLF : 0.9230 (+1.41%)
MSCL.TO : 16.05 (-0.62%)
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy

First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled 11-month open-label...

MSCLF : 0.9230 (+1.41%)
MSCL.TO : 16.05 (-0.62%)

Business Summary

Satellos Bioscience Inc. is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience...

See More

Key Turning Points

3rd Resistance Point 1.0087
2nd Resistance Point 0.9743
1st Resistance Point 0.9487
Last Price 0.9230
1st Support Level 0.8887
2nd Support Level 0.8543
3rd Support Level 0.8287

See More

52-Week High 1.0000
Last Price 0.9230
Fibonacci 61.8% 0.7622
Fibonacci 50% 0.6887
Fibonacci 38.2% 0.6152
52-Week Low 0.3774

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar